OTC SHOTCALLER (CYBERMITCH GOT ME LOOKING HERE)
Here you go
-- BTG...(Actually it BTG PLC) is no longer , they were bought out for 4.2 BILLION DOLLARS by BOSTON SCIENTIFIC in 2019.
They were not a middle man , BTG stood for the British Technology Group and had been around for years in Biopharma and other items.
BTG had connections with Bioclonetics some two decades ago +/- in some dealing , so was a long long long time ago. Charles C and the Bioclonetics Inc have gone through many changes since then and "It is what it is today".
-- Hmm BOSTON SCIENTIFIC,
that would be a good network partner. Big Pharma
in late November 2018 Boston Scientific announced it would acquire BTG for $4.2 billion. The transaction was due to complete in August 2019.
-- As far as Patents and what Bioclonetics has (has already been posted)... I think Charles C is just fine protecting what Bioclonetics has and understands the law there very well. I doubt if he googles anything to do about patents , protecting intellectual Property and the such, he is the "google answer to that" LOL
. All good here, I am happy with Charles C and so glad he came along (with the others) , GAME CHANGER.
-- Charles S Cotropia , see highlighted part about Patents , Protection
Charles S. Cotropia
Charles Cotropia is a co-founder and CEO/President of BioClonetics. He holds a JD
degree from Cornell University and a Bachelor of Science Degree in Aerospace
Engineering from the Univ. of Texas- Austin. Charles worked as a stress analysis
engineer at Lockheed Aircraft before attending Law School at Cornell Univ., IthacaNY. After graduating from Cornell Law School, Charles began his 44 year legal career
in Dallas, Texas serving clients in the intellectual property law field. For 18 years, he
served as a partner in the firm Sidley Austin LLP, an international law firm, where he
represented clients in intellectual property law and related matters in the fields of
biotech, aerospace, oil and gas exploration, electronics, software and related fields. His legal career spans 44 years of practice where he managed client matters in
numerous technologies involving patenting, licensing and enforcing intellectual
property rights. His practice included representing Fortune 500, as well as mid to
small, companies and individual inventors and entrepreneurs. He has drafted and
prosecuted over 800 patents in the US and foreign countries and has litigated
intellectual property cases in Federal and State Courts.
In addition, Charles also
served as Vice-President of BioClonetics from 2009 until 2017. before becoming
President of the Company